ANGPT2

ANGPT2 Full Name

angiopoietin 2

ANGPT2 Introduction

ANGPT2 encodes angiopoietin-2, a secreted glycoprotein that shares structural homology with ANGPT1 as a Tie2 receptor ligand but executes fundamentally distinct and context-dependent effects on the vasculature. ANGPT2 is predominantly expressed by endothelial cells, where it is stored within Weibel-Palade bodies — specialized secretory granules that release their contents in response to inflammatory cytokines, hypoxia, or growth factor stimulation. The core functional distinction between ANGPT2 and its sibling ANGPT1 lies in their opposing actions at Tie2: while ANGPT1 is a potent constitutive agonist that stabilizes blood vessels, ANGPT2 functions primarily as a competitive antagonist that disrupts ANGPT1-mediated Tie2 activation. By blocking Tie2 signaling, ANGPT2 loosens endothelial cell-matrix contacts, increases vascular permeability, and promotes a plastic, destabilized state that is permissive for angiogenic sprouting — a physiological remodeling response that becomes pathological when sustained chronically. However, the biology of ANGPT2 is more nuanced than a simple binary agonist/antagonist model. In lymphatic endothelial cells, where Tie2 expression is also present, ANGPT2 acts as a genuine agonist and is essential for normal lymphatic vessel development and function. Furthermore, during acute inflammation, proteolytic cleavage of the orphan receptor Tie1 converts ANGPT2 from a Tie2 antagonist into a partial agonist, initiating a positive feedback loop that amplifies endothelial cell remodeling signals.

Figure 1. Scheme of angiopoietin-2 signaling and potential therapeutic targets in kidney diseases. (Source: Luo AJ, et al. 2024)

This versatile ligand is strongly implicated in multiple human diseases. Germline mutations in ANGPT2 are causal for lymphatic malformation 10, underscoring its non-redundant role in lymphatic vascular morphogenesis. Circulating ANGPT2 is a well-validated prognostic biomarker in acute respiratory distress syndrome, where elevated levels correlate with disease severity and mortality. In oncology, ANGPT2 overexpression is documented in a variety of solid tumors including oral squamous cell carcinoma and small cell lung cancer, where it promotes tumor angiogenesis, epithelial-mesenchymal transition, and metastatic dissemination. Therapeutic modulation of ANGPT2 activity — through monoclonal antibodies, bispecific molecules, or engineered Tie2 agonists — represents an active area of translational research with several candidates undergoing clinical evaluation for vascular anomalies, cancer, and inflammatory disorders.

Alternate Names for ANGPT2

ANGPT2; angiopoietin 2; angiopoietin-2; Ang2; ANG-2; Tie2-ligand; angiopoietin-2B; angiopoietin-2a; ANG2; AGPT2; nesvacumab; 1296818-77-3

• 1. Gillen J, et al. Angiopoietin-1 and Angiopoietin-2 Inhibitors: Clinical Development. Curr Oncol Rep. 2019 Feb 26;21(3):22.
  2. Luo AJ, et al. Exploring Angiopoietin-2: Clinical Insights and Experimental Perspectives in Kidney Diseases. Kidney Int Rep. 2024 Sep 6;9(12):3375-3385.